Intellectual Product – Page 4

Recent Developments in Building Measurable Patient Support Programs (2025)

1 month ago talkbio0Tagged 2025, care activity, collaborative healthcare, Efficiency, Financial cost, measurable outcomes, Medicare reforms, Programs - Publication Format, trends qualifier

patient support programs; measurable outcomes; collaborative healthcare; 2025 trends; Medicare reforms; cost efficiency; access to care

LEO Pharma Acquires Exclusive Global Rights for Boehringer Ingelheim’s Psoriasis Drug Spevigo in €90 Million Deal

1 month ago talkbio0Tagged Boehringer Ingelheim, Drug licensing, Generalized pustular psoriasis, IL1RAP protein, human, Immunology, News [Publication Type], Partnership, Pharma, Psoriasis, spesolimab, Spevigo

LEO Pharma; Boehringer Ingelheim; Spevigo; spesolimab; psoriasis; GPP; drug licensing; immunology; IL-36 receptor; partnership; biotech news

Takeda’s Oveporexton Succeeds in Two Phase III Trials, Paving Way for Narcolepsy Drug Filings

1 month ago talkbio0Tagged Clinical Trials, File (record), Narcolepsy, Narcolepsy type 1, orexin agonist, oveporexton, Phase 3 Clinical Trials, Takeda, United States Food and Drug Administration

Takeda; Oveporexton; narcolepsy; Phase III trials; orexin agonist; FDA filing; Narcolepsy Type 1; clinical trial results

WHO to Develop Guidelines for Gilead’s Twice-Yearly HIV PrEP Injection (Lenacapavir)

1 month ago talkbio0Tagged Approved, Gilead, Guidelines, HIV Prevention, Lenacapavir, PREP gene, twice-yearly injection, United States Food and Drug Administration, World Health Organization

WHO; Gilead; Lenacapavir; twice-yearly injection; PrEP; HIV prevention; guidelines; FDA approval

FDA Rejects Capricor’s Cell Therapy for Duchenne Muscular Dystrophy

1 month ago talkbio0Tagged Capricor Therapeutics, Cardiomyopathies, Cell Therapy, Clinical Data, Complete, deramiocel, HOPE-3 trial, Muscular Dystrophy, Duchenne, Phase 3, Rejection, Response process, United States Food and Drug Administration

FDA rejection; Capricor Therapeutics; deramiocel; Duchenne muscular dystrophy; DMD; cell therapy; cardiomyopathy; clinical data; Phase 3 HOPE-3 trial; Complete Response Letter

FDA Commissioner Makary Proposes Fast-Track Drug Review Vouchers Tied to Lower US Prices, Without Detailing Criteria

1 month ago talkbio0Tagged drug price, fast-track approval, Makary, national priority review vouchers, Parity, pilot program, Prices, United States Food and Drug Administration

FDA; Makary; national priority review vouchers; drug pricing; fast-track approval; price parity; pilot program

Trump Threatens 200% Tariffs on Pharma Imports, Proposes 1-Year Grace Period for Onshoring

2 months ago talkbio0Tagged 200, Biopharma, drug imports, grace, Investments, Menstruation, onshoring, Pharma, pharmaceutical tariffs, Policy, tariff, Transplant Registry Unified Management Program, U.S.

Trump; pharmaceutical tariffs; 200% tariff; grace period; pharma manufacturing; drug imports; US supply chain; onshoring; policy; biopharma investments